Literature DB >> 25425528

Should small papillary thyroid cancer be observed? A population-based study.

Naris Nilubol1, Electron Kebebew.   

Abstract

BACKGROUND: Some centers have advocated selecting patients with small papillary thyroid cancer (PTC) to undergo active surveillance without surgical treatment. The objectives of the current study were to analyze thyroid cancer (TC)-related mortality in a population-based cohort and to determine the impact of small PTCs (defined as tumors ≤ 2 cm in greatest dimension) on TC-related mortality.
METHODS: Data on patients with TC of follicular cell origin from the National Cancer Institute's Surveillance, Epidemiology, and End Results 17 Registries database (1988-2007) were used to analyze the characteristics of PTCs ≤ 2 cm in patients who died from TC-related causes. The effects of clinical features on disease-specific survival were analyzed.
RESULTS: Over the 20-year study period, the rate of TC-related mortality was 2.8% (n = 1753 of 61,523 patients). Of the patients who died from TC-related causes, 38% had PTC, 10% had follicular TC, and 31.3% had anaplastic TC. PTCs ≤ 2 cm accounted for 12.3% of TC-related mortalities. Compared with patients who did not experience TC-related mortality from PTCs ≤ 2 cm, there were significantly higher rates of men (30% vs 17%; P < .01), patients aged ≥ 45 years (92% vs 52%; P < .01), tumors measuring >1 cm (59% vs 46%; P < .01), extrathyroid extension (41% vs 11%; P < .01), lymph node metastases (77% vs 28%; P < .01), and distant metastases (31% vs 1%; P < .01) among the patients who died from PTCs ≤ 2 cm. Independent risk factors for death from PTCs ≤ 2 cm included age ≥ 45 years, lymph node and distant metastases, extrathyroid extension, and undergoing less than thyroid lobectomy.
CONCLUSIONS: Because 12.3% of patients who experienced TC-related deaths had PTCs ≤ 2 cm despite undergoing thyroidectomy, the current results indicate that nonoperative management for patients who have PTCs ≤ 2 cm should be used with caution. Patients aged ≥ 45 years with PTCs ≤ 2 cm should undergo thyroidectomy. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Surveillance, Epidemiology, and End Results Program; cancer-specific survival; mortality; prognostic factor; thyroid cancer

Mesh:

Year:  2014        PMID: 25425528      PMCID: PMC4368467          DOI: 10.1002/cncr.29123

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Clinical and pathological characteristics of incidental and nonincidental papillary thyroid microcarcinoma in 339 patients.

Authors:  Ioannis Vasileiadis; Theodore Karatzas; Dimitrios Vasileiadis; Stylianos Kapetanakis; Georgios Charitoudis; Efthimios Karakostas; Gregory Kouraklis
Journal:  Head Neck       Date:  2013-06-18       Impact factor: 3.147

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

4.  Prognosis of patients with thyroid cancer who do not undergo surgical treatment: a SEER database analysis.

Authors:  Alvaro Sanabria; Luis C Domínguez; Valentín Vega; Camilo Osorio
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

5.  Lymph node metastases in differentiated thyroid cancer under 2 cm.

Authors:  Rishindra M Reddy; Perry W Grigsby; Jeffrey F Moley; Bruce L Hall
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

6.  Annual financial impact of well-differentiated thyroid cancer care in the United States.

Authors:  Carrie C Lubitz; Chung Y Kong; Pamela M McMahon; Gilbert H Daniels; Yufei Chen; Konstantinos P Economopoulos; G Scott Gazelle; Milton C Weinstein
Journal:  Cancer       Date:  2014-01-30       Impact factor: 6.860

7.  Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases.

Authors:  Xiao-Min Yu; Yin Wan; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg       Date:  2011-10       Impact factor: 12.969

8.  Gender is an age-specific effect modifier for papillary cancers of the thyroid gland.

Authors:  Briseis A Kilfoy; Susan S Devesa; Mary H Ward; Yawei Zhang; Philip S Rosenberg; Theodore R Holford; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-17       Impact factor: 4.254

9.  Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution.

Authors:  R Sciuto; L Romano; S Rea; F Marandino; I Sperduti; C L Maini
Journal:  Ann Oncol       Date:  2009-10       Impact factor: 32.976

10.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

View more
  20 in total

1.  Papillary Thyroid Microcarcinoma: Reclassification to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): a Retrospective Clinicopathologic Study.

Authors:  Khurram Shafique; Virginia A LiVolsi; Kathleen Montone; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

2.  Patient-Reported Dysphagia After Thyroidectomy: A Qualitative Study.

Authors:  Brittany N Krekeler; Elizabeth Wendt; Cameron Macdonald; Jason Orne; David O Francis; Rebecca Sippel; Nadine P Connor
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-04-01       Impact factor: 6.223

3.  Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.

Authors:  Shweta Kotian; Lisa Zhang; Myriem Boufraqech; Kelli Gaskins; Sudheer Kumar Gara; Martha Quezado; Naris Nilubol; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2017-06-09       Impact factor: 12.531

Review 4.  Research Review of Thermal Ablation in the Treatment of Papillary Thyroid Carcinoma.

Authors:  Di Ou; Chen Chen; Tian Jiang; Dong Xu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

5.  Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.

Authors:  P W Rosario; G Mourão; M R Calsolari
Journal:  J Endocrinol Invest       Date:  2018-10-23       Impact factor: 4.256

6.  A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma.

Authors:  Juan P Brito; Yasuhiro Ito; Akira Miyauchi; R Michael Tuttle
Journal:  Thyroid       Date:  2015-11-05       Impact factor: 6.568

7.  Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.

Authors:  Amit Mehta; Lisa Zhang; Myriem Boufraqech; Yi Liu-Chittenden; Yaqin Zhang; Dhaval Patel; Sean Davis; Avi Rosenberg; Kris Ylaya; Rachel Aufforth; Zhuyin Li; Min Shen; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2015-05-05       Impact factor: 13.801

8.  Ultrasound Image Classification of Thyroid Nodules Using Machine Learning Techniques.

Authors:  Vijay Vyas Vadhiraj; Andrew Simpkin; James O'Connell; Naykky Singh Ospina; Spyridoula Maraka; Derek T O'Keeffe
Journal:  Medicina (Kaunas)       Date:  2021-05-24       Impact factor: 2.430

Review 9.  Total Thyroidectomy with Central Node Dissection is a Valuable Option in Papillary Thyroid Cancer Treatment.

Authors:  Marija Pastorčić Grgić; Boris Stubljar; Pavao Perše; Mirta Zekan Vučetić; Sanda Šitić
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780

10.  Risk Factors for Contralateral Occult Carcinoma in Patients With Unilateral Papillary Thyroid Carcinoma: A Retrospective Study and Meta-Analysis.

Authors:  Fan Zhang; Boyuan Zheng; Xiaohui Yu; Xichang Wang; Shiwei Wang; Weiping Teng
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-12       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.